Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Alkenylated phenolics from Syzygium lineatum with antiproliferative activity against chronic myeloid leukemia cells

Franklin V. Ibana, Von Novi O. de Leon, Joe Anthony H. Manzano, Agnes L. Castillo, Allan Patrick G. Macabeo.




Abstract

Syzygium lineatum is traditionally used by Filipinos as an anticancer regimen and food flavouring in the Philippines. However, its medicinal potential is yet to be validated. Herein, we report the antiproliferative and cytotoxic activities of S. lineatum extracts, sub-extracts, and alkenylated phenolic constituents gingkol (1) and bilobol (2) along with β-sitosterol (3) and a mixture of fatty acids (4–6) in vitro and in silico. Fractions 2 and 4 (SlPE4) from the biologically active petroleum ether sub-extract (SlPE), showed moderately strong antiproliferative activity against chronic myeloid leukemia (CML) cells (K-562). Chromatographic purification of fraction SlPE4 yielded antiproliferative compounds 1 and 2 against K-562 cells while SlPE2 afforded 3–6. Bilobol (2), an alkenylated resorcinol, showed better selectivity in vitro compared to the phenolic congener, gingkol (1) highlighting the importance of increased hydroxylation in the aromatic structure of the compounds. To elucidate their putative mechanisms of action, molecular docking studies were performed versus establishing the CML targets BCR::ABL1 tyrosine kinase, c-Src kinase, and protein kinase B. In silico results showed moderate to good binding affinities of 1 and 2 in the active sites of the target kinases. Overall, the study validates the purported Philippine traditional anticancer use of S. lineatum, especially its constituents gingkol (1) and bilobol (2).

Key words: Syzygium lineatum, anticancer, chronic myeloid leukemia cells, molecular docking, gingkol, bilobol






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.